Rossari Biotech Share Price Target 2027: Is Rs 450 Realistic? Bull Case Points to Rs 547

Investors weighing a Rossari Biotech target price for 2027 should start with where the stock sits today. At Rs 423.15 on 5 November 2026, it is 35.3% below its 52-week high of Rs 654.00 and 12.8% above its 52-week low of Rs 375.00. That range spans 74% from low to high, so the entry point matters as much as the Rossari Biotech price forecast itself.

This article builds the Rossari Biotech share price target from reported numbers only: five years of annual results, the last five quarters, the latest shareholding pattern and current valuation ratios from company filings and exchange data. Each scenario states its assumptions, so you can trace how the base case, the bull case and the downside risk level were reached and test them against your own view.

Click Here – Get Free Investment Predictions

Rossari Biotech Stock Analysis: Company Overview and Key Stats

Rossari Biotech (NSE: ROSSARI) has a market capitalisation of Rs 2,337 crore. In FY26 it reported revenue of Rs 2,419 crore and net profit of Rs 149.21 crore. The table collects the figures the Rossari Biotech share price target is built on.

Metric	Value
Company	Rossari Biotech
NSE Ticker	ROSSARI
CMP (5 November 2026)	Rs 423.15
52-Week High	Rs 654.00
52-Week Low	Rs 375.00
Market Cap	Rs 2,337 crore
PE Ratio (TTM)	15.30
Industry PE	32.55
Price to Book	1.66
Return on Equity	10.85%
Debt to Equity	0.28
EPS (TTM)	Rs 27.57
Dividend Yield	0.12%
12-Month Base Target	Rs 450
Bull Case	Rs 547
Downside Risk Level (not a target)	Rs 337

Why Is Rossari Biotech Share Price Target Set at Rs 450 for 2027?

The arithmetic is short. Trailing EPS of Rs 27.57 grown for one year gives a forward EPS estimate of Rs 29.44, and multiplying it by the unchanged PE of 15.30 gives the Rs 450 base-case Rossari Biotech stock target. The bull case adds faster earnings growth and a higher multiple, while the downside risk level assumes flat earnings and a lower multiple.

Earnings Growth Behind the Rossari Biotech Target Price: Five Years of Results

Rossari Biotech grew revenue from Rs 1,495 crore in FY22 to Rs 2,419 crore in FY26, a compound annual growth rate of 12.8%. Net profit grew more slowly, from Rs 97.69 crore to Rs 149.21 crore (11.2% a year), which points to margin pressure alongside the sales growth.

Financial Year	Revenue (Rs Cr)	Net Profit (Rs Cr)	EPS (Rs)	Dividend per Share (Rs)
FY22	1,494.97	97.69	17.70	0.50
FY23	1,661.37	107.26	19.38	0.50
FY24	1,838.00	130.69	23.62	0.50
FY25	2,084.30	136.38	24.63	0.50
FY26	2,418.74	149.21	26.93	0.50

FY26 revenue growth was 16.0%, faster than the four-year average of 12.8%, and net profit moved up 9.4%. EPS rose from Rs 23.62 in FY24 to Rs 26.93 in FY26. The FY27 outlook depends on whether that EPS estimate keeps compounding.

Margins and the Latest Quarter

Rossari Biotech converted 6.2% of FY26 revenue into net profit, against 6.5% in FY25, within a five-year range of 6.2% to 7.1%. EBITDA margin was 12.8% in FY26 versus 13.0% in FY25.

In the September 2026 quarter, revenue was Rs 698.16 crore, up 18.8% from the same quarter a year earlier, while net profit of Rs 38.91 crore was up 5.5%. EBITDA came in at Rs 87.58 crore, up 19.1% year on year. The next quarterly result is the first test of whether the earnings assumption holds.

Balance Sheet and Cash Flow

Debt to equity stands at 0.28, and shareholders' equity grew from Rs 805.16 crore in FY22 to Rs 1,333 crore in FY26. Operating cash flow in FY26 was Rs 65.07 crore against capital expenditure of Rs 264.67 crore, leaving negative free cash flow of Rs 199.60 crore. In FY25 free cash flow was negative at Rs 21.07 crore.

Valuation Check for the Rossari Biotech Stock Target: PE, Price to Book and ROE

At a PE of 15.30 against an industry PE of 32.55, Rossari Biotech trades at a discount to its industry. Price to book is 1.66 on a book value of Rs 254.11 per share, and return on equity is 10.85%. A PE of 15.30 equals an earnings yield of 6.5%, and the FY26 dividend of Rs 0.50 per share gives a yield of 0.12%.

Shareholding Pattern and Institutional Holding

Promoters held 68.14% of Rossari Biotech in September 2026, and promoter holding has stayed near 68.14% since September 2025. Foreign institutional investors (FII) held 1.84% and domestic institutions (DII) held 14.19%, which puts total institutional holding at 16.03%. FII holding fell from 2.69% in September 2025 to 1.84% in September 2026. Public shareholders own the remaining 15.83%. A meaningful institutional holding adds a layer of research coverage and trading depth.

Rossari Biotech Share Price Targets for the Short Term and 12 Months

Short Term Rossari Biotech Stock Target Levels: Technical Setup

At Rs 423.15 on 5 November 2026, Rossari Biotech trades below its 50-day simple moving average of Rs 439.42 and below its 200-day exponential moving average of Rs 497.29. The 14-day RSI reads 44.3, which is neutral territory, and the MACD line sits above its signal line. The nearest resistance level is Rs 439.42 (50-day simple moving average) and the nearest support is Rs 375.00 (52-week low). A sustained move above Rs 439.42 would improve the short-term setup, while a close below Rs 375.00 would shift attention to the next support.

12 Month Rossari Biotech Target Price for 2027

The 12-month target of Rs 450 means a move of 6.3% up from Rs 423.15 over the next 12 months. It would still leave the stock 31.2% below its 52-week high of Rs 654.00.

How EPS Growth and PE Multiple Change the Rossari Biotech Target Price

EPS Growth	PE 12.24	PE 15.30	PE 17.59
0.0% (EPS Rs 27.57)	Rs 337	Rs 422	Rs 485
6.8% (EPS Rs 29.44)	Rs 360	Rs 450	Rs 518
12.8% (EPS Rs 31.09)	Rs 381	Rs 476	Rs 547

Each cell multiplies the forward EPS estimate by the PE shown. Reading across a row shows what a de-rating or re-rating does to the Rossari Biotech price forecast, and reading down a column shows what earnings growth is worth at a fixed multiple.

Bull Case and Downside Risk for Rossari Biotech Stock Target in 2027

Bull Case Rs 547

The bull case Rossari Biotech price target needs EPS growth of 12.8%, which lifts forward EPS to Rs 31.09, and a PE multiple that rises 15% to 17.59. That gives Rs 547, 29.3% above the current price and below the 52-week high of Rs 654.00.

Downside Risk Level Rs 337

The downside risk level is not a target. It assumes EPS stays flat at Rs 27.57 and the PE falls 20% to 12.24. That gives Rs 337, 20.4% below the current price and below the 52-week low of Rs 375.00.

Scenario	EPS Growth	PE Multiple	Price (Rs)	Change vs CMP
Bull Case	12.8%	17.59	Rs 547	+29.3%
Base Case	6.8%	15.30	Rs 450	+6.3%
Downside Risk	0.0%	12.24	Rs 337	-20.4%

Key Risks to the Rossari Biotech Target Price for 2027

Growth Slowdown Risk for the Rossari Biotech Price Target

Revenue in the September 2026 quarter was up 18.8% year on year, and FY26 revenue growth was 16.0%. If growth slows from here, the EPS estimate behind the Rossari Biotech stock target will need revising.

Liquidity and Size Risk

Rossari Biotech has a market capitalisation of Rs 2,337 crore. Institutional holding is 16.03%, and promoters hold 68.14%. Stocks of this size can move sharply on small volumes, and exits can take longer than entries.

Valuation and Margin Risk

Net margin was 6.2% in FY26, so a small slip in costs moves profit noticeably. At a PE of 15.30 versus an industry PE of 32.55, a de-rating toward the downside-risk PE of 12.24 would cut the price even if earnings hold.

Market and Technical Risk

Technical indicators add short-term risk: the 14-day RSI is 44.3 and the MACD sits above its signal line. A broad fall in the Nifty 50 or the Sensex can override company fundamentals for weeks at a time.

How to Invest in Rossari Biotech

Start with the live price and volume. Any Rossari Biotech share price target is only as current as the data behind it, and the data here is as of 5 November 2026, so refresh the Rs 423.15 price before acting on any level.

Next, review the fundamentals yourself. The Univest Screener lets you check Rossari Biotech's PE, ROE, debt and shareholding in one place.

Check Rossari Biotech fundamentals on the Univest Screener

Then compare the three Rossari Biotech target price scenarios with your own view. If you expect EPS growth below 6.8%, the base case is too optimistic for you; if you expect more, the bull case deserves weight.

Decide your position size and exit levels before you buy. The support and resistance levels above can serve as reference points, but they are not recommendations.

Finally, place the order through a SEBI-registered broker or the Univest app, and review the position after each quarterly result. Consult a SEBI-registered advisor if you are unsure.

Download the Univest iOS App or Univest Android App to track Rossari Biotech live price and get daily stock recommendations.

Conclusion

The Rossari Biotech share price target for 2027 is Rs 450 in the base case, with Rs 547 as the bull case. The support for that view is arithmetic you can check: EPS grew 6.8% a year over FY24 to FY26, and the stock trades at a PE of 15.30. The risks are equally concrete, including a net margin of just 6.2% that leaves profit sensitive to costs and a downside scenario that cuts the price 20% if earnings stall. Use these numbers as a framework, check them against the latest filings, and size any position to your own risk appetite.

FAQs on Rossari Biotech Share Price Target 2027

What is the Rossari Biotech share price target for 2027?

Ans. The base-case Rossari Biotech share price target for 2027 is Rs 450, which is 6.3% above the price of Rs 423.15 on 5 November 2026. The bull case is Rs 547 and the downside risk level, which is not a target, is Rs 337. All three come from one method: forward EPS multiplied by a PE multiple, using only reported results. They are model estimates and not guaranteed outcomes, and the next quarterly result is the first check on the EPS assumption.

What is the Rossari Biotech share price today?

Ans. As of 5 November 2026, 11:37 AM IST, Rossari Biotech (NSE: ROSSARI) trades at Rs 423.15, up 0.65% on the day. That is 35.3% below the 52-week high of Rs 654.00 and 12.8% above the 52-week low of Rs 375.00. The market capitalisation of Rs 2,337 crore places it among small-cap stocks. Prices change through the trading session, so check the live quote before acting on any level in this article.

Is Rossari Biotech a buy or sell at the current price?

Ans. The data points both ways. On the positive side, EPS has grown 6.8% a year over FY24 to FY26 and the base case implies 6.3% upside; on the cautious side, the net margin is a thin 6.2%, and the downside risk level of Rs 337 is 20% below the current price. Whether Rossari Biotech fits your portfolio depends on your time horizon, position size and risk appetite. Consult a SEBI-registered advisor before investing, as this article is not investment advice.

What are the bull case target and downside risk level for Rossari Biotech shares?

Ans. The bull case in the Rossari Biotech share price target for 2027 is Rs 547, which assumes 12.8% EPS growth and a PE of 17.59, a 15% re-rating from today's multiple. That is 29.3% above the current price and below the 52-week high of Rs 654.00. The downside risk level is Rs 337, which assumes flat EPS and a PE of 12.24, 20% lower than today. It sits 20.4% below the current price and below the 52-week low of Rs 375.00, and it marks a risk to watch, not a target.

What are the main risks to the Rossari Biotech price target?

Ans. Four risks matter most for the Rossari Biotech share price target: slower revenue or profit growth, a PE de-rating, thin liquidity or size risk, and weakness in the broader market. With a market capitalisation of Rs 2,337 crore, the stock can move sharply on small volumes, and exits can take longer than entries. A fall to the downside-risk PE of 12.24 would cut the price even if earnings hold.

What is the PE ratio of Rossari Biotech and how does it compare with the industry?

Ans. The PE ratio of Rossari Biotech is 15.30, against an industry PE of 32.55, which is a discount to the industry. Price to book is 1.66 and return on equity is 10.85%, and the PE equals an earnings yield of 6.5%. The base case holds the PE unchanged, so the Rossari Biotech share price target moves only with earnings, while the bull and downside scenarios change the multiple by +15% and -20%.

Who owns Rossari Biotech, and what is the promoter holding?

Ans. Promoters held 68.14% of Rossari Biotech in September 2026. FII held 1.84%, DII held 14.19% and the public held 15.83%. Together the two institutional groups hold 16.03%. Shareholding is filed every quarter, so it is worth rechecking after each result.

What were Rossari Biotech's latest quarterly results?

Ans. In the September 2026 quarter, Rossari Biotech reported revenue of Rs 698.16 crore (up 18.8% year on year) and net profit of Rs 38.91 crore (up 5.5%). For comparison, FY26 full-year revenue growth was 16.0% and net profit moved up 9.4%. Each new quarter either supports or weakens the EPS growth of 6.8% assumed in the base case.